The Bayer Group is restructuring its core life science businesses through a series of portfolio, efficiency and structural measures that will result in the reduction of approximately 12,000 jobs worldwide by the end of 2021. Pharmaceuticals will account for approximately 900 jobs in R&D and 350 positions related to the factor VIII facility in Wuppertal; 1,100 jobs associated with the reorganization at Consumer Health; 4,100 positions at Crop Science as the result of integrating the acquired ...